An interventional study of Bladder flap formation in Cesarean Scar Defect, sponsored by Montefiore Medical Center. Recruiting at 2 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Montefiore Medical Center · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 199 studies in Cicatrix with a site in United States — 25 open to participants now, 35 under way, 2 of them phase 3. Cicatrix · United States.
Among the 199 studies in Cicatrix with a site in United States, this one is the 4th largest by planned enrollment of the 185 interventional ones that give a count, is one of 6 that started in 2026, is one of 131 with no phase, reaches primary completion later than 20 of the 34 other live ones, and was the 196th registered.
616 studies on the registry are indexed under Cicatrix; 117 are open to participants now.
Browse Cicatrix studies →25 of the 199 studies in Cicatrix with a site in United States are open now. Recruiting first, the newest first:
AbbVie · Sites in United States
Ages 22+
University of California, Davis · Sites in United States
Ages 18+
Columbia University · Sites in United States
Ages 18+
Medstar Health Research Institute · Sites in United States
Ages 18+
AVAVA, Inc. · Sites in United States
Ages 18–70 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 69 Cicatrix studies recruiting now, 34 (49%) set no upper age limit and 31 (45%) stop at 75 or younger; 11 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
199 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 34 · Phase 3 6 · Phase 4 5
First in 1995; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 338 is above the median of 40 across 515 interventional studies indexed under Cicatrix.
Median enrollment 25 across the 185 interventional studies, 101 across the 13 observational. Of the 131 that completed or were terminated, 56 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 199 have an industry lead sponsor. The 10 most frequent:
Montefiore Medical Center is the lead sponsor of 417 studies on the registry; 69 are open to participants now.
Of its 89 completed or terminated interventional studies of FDA-regulated products, 77 (87%) have results posted.
Montefiore Medical Center has 2 studies filed under Cicatrix — fewer than ten, so there is no comparison to draw.
9 of the studies in Cicatrix with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05478551Phase 3Henry Ford Health SystemRandomized Controlled Trial Examining the Efficacy of Botulinum Toxin in Biopsy Scar Minimization | 2026-12-30 |
| NCT05758181University of California, DavisUndermining Apices in Surgical Wounds | 2026-12-31 |
| NCT06448481University of California, DavisAesthetic Outcome of Intra-dermal Versus Transcutaneous Purse-string Closure | 2027-01-01 |
| NCT06171386Wake Forest University Health SciencesMicroneedling vs Dermabrasion for Early Facial Scar Resurfacing | 2027-04 |
| NCT06903208Columbia UniversityRFA for Superficial Lipomas | 2027-07 |
Add all 9 to your calendar (.ics) → With an account.
Among the 199 studies in Cicatrix with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this trial is to examine if the completion or omission of a bladder flap impacts the location and formation of cesarean scar niche in women undergoing primary cesarean section. The main question it aims to answer is if omission of a bladder flap changes the prevalence of cesarean scar niche on a 6-8 week postpartum ultrasound. Researchers will compare participants that have a bladder flap made to those that have a bladder flap omitted at time of their primary cesarean delivery. Participants will have routine postpartum care and be asked to return for a 6-8 week postpartum transvaginal ultrasound.
As the rate of cesarean deliveries increases globally, the importance of a cesarean scar niche (CSN) has evolved into a significant clinical concern with long term obstetric and gynecologic implications including increasing risk for placenta accreta spectrum (PAS) in future pregnancies and abnormal uterine bleeding. In fact, the main cause of PAS is placentation into uterine scars secondary to cesarean deliveries
Bladder flap formation is a standard step in cesarean deliveries and involves dissecting the bladder off the uterus to push it inferiorly to allow better access to the lower uterine segment for hysterotomy and decrease risk of bladder injury. The lower uterine segment is targeted for hysterotomy as it has been shown that the proportion of muscle tissue and the thickness of the wall of the uterus increases as one travels from the cervix to the fundus. Therefore, by making an incision in the lower uterine segment, the surgeon has less tissue to go through to deliver the fetus and disrupts less muscle to preserve uterine myometrial integrity. While studies have suggested bladder flap omission in primary cesarean deliveries does not increase intraoperative complications and reduces operating time. CSN assessment was not an outcome evaluated in these studies and the decision to omit or perform a bladder flap is at the discretion of the surgeon.
Previous studies have looked at different surgical techniques and different cervical dilations at time of cesarean delivery and the impact on niche formation and location. There has been no consensus on hysterotomy or other surgical techniques to decrease risk of CSN formation. To our knowledge, there have not been studies that have assessed postoperative CSN in relation to completion or omission of a bladder flap prior to hysterotomy. As such, the investigator team hypothesizes that omission of a bladder flap lends itself to a more cephalad hysterotomy and potentially more clinically significant CSNs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to this arm will have the bladder flap step omitted prior to low transverse hysterotomy formation. Participants will not need to alter their postoperative or postpartum care.
Participants randomized to this arm will have a bladder flap formed using standard procedure during the cesarean delivery prior to low transverse hysterotomy and delivery of the infant. As with the 'Bladder flap omission' arm, participants will not need to alter their postoperative or postpartum care.
Procedure: Bladder flap formation
Participants in this arm will have a bladder flap completed at the time of their cesarean delivery.
Presence of cesarean scar niche
A dichotomous measure of the presence or absence of a cesarean scar niche, as defined by a residual myometrial thickness of \<3mm at the scar level, detected on transvaginal ultrasound. The presence of a cesarean scar niche increases risk for gynecologic complaints and abnormal placentation in subsequent pregnancies.
Time frame: From enrollment to transvaginal ultrasound, completed approximately 6-8 weeks postpartum
Distance of cesarean scar niche from internal os
Sonographic distance of cesarean scar niche from internal cervical os, measured in millimeters, on postpartum transvaginal ultrasound. The investigator team hypothesizes that a scar further from the internal os has increased risk for abnormal placentation in future pregnancies.
Time frame: From enrollment to time of transvaginal ultrasound, completed approximately 6-8 weeks postpartum
Size of cesarean scar niche
Sonographic dimensions of length and width of cesarean scar niche, measured in mm, on transvaginal ultrasound. The investigator team hypothesizes that larger niches are associated with increased risk of abnormal placentation in future pregnancies and increased risk of future gynecologic complaints.
Time frame: From enrollment to time of transvaginal ultrasound, completed approximately 6-8 weeks postpartum
Measurement of residual myometrium
Sonographic measurement of residual myometrium in mm by transvaginal ultrasound. Thinner residual myometrium may imply a larger defect, increased risk for abnormal placentation or formation of a uterine window in future pregnancies.
Time frame: From enrollment to time of transvaginal ultrasound, completed approximately 6-8 weeks postpartum
Size of cesarean scar defect in subsequent pregnancy
Sonographic measurement of dimensions (length and width) of cesarean scar defect in subsequent pregnancy, measured in mm, to assess if larger postpartum niches are associated with larger defects in subsequent pregnancies as they may carry increased risk of morbidity in the pregnancy.
Time frame: From time of enrollment to time of subsequent pregnancy, up to 5 years following baseline pregnancy
Cases of abnormal placentation in subsequent pregnancies
If encountered in a subsequent pregnancy, the number of cases of abnormal placentation in the cesarean scar and placenta accreta spectrum will be summarized. Ultrasound evidence of placenta accreta spectrum include disappearance of the border between placenta and myometrium, placental lacunae, increased vasculature from placenta extending into myometrium, abnormal invasion of placenta into surrounding organs and structures. Pathology will be used to confirm the number of cases of placenta accreta spectrum.
Time frame: From time of enrollment to time of subsequent pregnancy, up to 5 years following baseline pregnancy
Uterine Position/Flexion
As an anteverted and retroflexed uterus is commonly the result of a cesarean delivery and scar tissue altering anatomical position, the clinicians will observe if a bladder flap alters position of the uterus. At the 6 week transvaginal ultrasound, the position of the uterus as anteverted or retroverted and flexion as anteflexed or retroflexed will be recorded. In the sagittal plane on transvaginal ultrasound, if the cervix appears on the viewer's right or left, the position is anteverted or retroverted, respectively. The anterior or posterior flexion of the fundus will define anteflexion and retroflexion, respectively
Time frame: From enrollment to time of transvaginal ultrasound, completed approximately 6-8 weeks postpartum
Number/percentage of Operative and Postoperative Complications
Patient charts will be reviewed to summarize the number/percentage of surgical complications in each arm. This includes complications such as damage to surrounding structures, hemorrhage, hematoma formation, surgical site infections.
Time frame: From enrollment to time of transvaginal ultrasound, completed approximately 6-8 weeks postpartum
Plan to share: Yes — De-identified individual participant data (IPD) that underlie the results reported in future publications will be made available to qualified researchers upon request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Beginning 6 months after trial publication for a period of up to 5 years.
Access criteria: Requests will require a data use agreement and a proposal review by the study team.
Started Oct 2026 (actual). Primary completion is estimated for Sep 2027, 10 months after the start.
Of 175 non-industry interventional studies with no phase under Cicatrix, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 36. This study's planned 10 months is below that.
Counting every sponsor, half of 208 studies reached it within 18 months; a quarter within 8 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.